Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
HUMAN PLASMA PROTEIN >90% GAMMA GLOBULIN HUMAN TETANUS IMMUNOGLOBULIN PH. EUR.
Baxter Healthcare Limited
HUMAN PLASMA PROTEIN >90% GAMMA GLOBULIN HUMAN TETANUS IMMUNOGLOBULIN PH. EUR.
%v/v
Solution for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
2013-03-31
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tetabulin S/D 250 IU/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human Tetanus Immunoglobulin One pre-filled syringe of Tetabulin S/D 250 IU (1ml) contains: Human tetanus immunoglobulin 250 IU human protein 100-170g/l (of which at least 90% are immunoglobulin G) Max. 1gA content: 4.8mg/ml For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. The product is a clear or slightly opalescent, colourless to pale yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS 1. Post-exposure prophylaxis: Immediate prophylaxis after tetanus prone injuries in patients not adequately vaccinated, in patients whose immunization status is not known with certainty, and in patients with severe deficiency in antibody production. 2. Therapy of clinically manifest tetanus. Active tetanus vaccination should always be administered in conjunction with tetanus immunoglobulin unless there are contraindications or confirmation of adequate vaccination. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _Prophylaxis: _of tetanus prone wounds o 250 IU, unless the risk of tetanus is thought to be extremely high o the dose may be increased to 500 IU in infected wounds, where surgically appropriate treatment cannot be achieved within 24 hours deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign body injury (e.g. bites, stings or shots). _Therapy:_ o Available data suggest the value of human tetanus immunoglobulin in the treatment of clinically manifest tetanus using single doses of 3,000 to 6,000 IU intramuscularly in combination with other appropriate clinical procedures. Consideration should also be given to other official guidance on the appropr Read the complete document